Vanguard Global Advisers’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$462K Buy
46,487
+220
+0.5% +$1.94K ﹤0.01% 2125
2026
Q2
$375K Buy
46,267
+17,094
+59% +$125K ﹤0.01% 2231
2026
Q1
$186K Buy
+29,173
New +$188K ﹤0.01% 2474

Other funds holding PBYI

Vanguard Global Advisers's PBYI Position: Q3 2026 in Review

Vanguard Global Advisers increased its Puma Biotechnology (PBYI) stake by 0.48% in Q3 2026, buying an estimated $1.94K and bringing the position to 46,487 shares worth $462K. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

Vanguard Global Advisers first reported a position in PBYI in Q1 2026 and has held it in 3 quarters since. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • Vanguard Global Advisers held 46,487 shares of Puma Biotechnology worth $462K as of Q3 2026.
  • Vanguard Global Advisers bought 220 Puma Biotechnology shares in Q3 2026, an estimated $1.94K.
  • Puma Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2125 holding.
  • Vanguard Global Advisers first reported a position in Puma Biotechnology in Q1 2026 and has held it in 3 quarters since.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.